Louise Gagnon
ATX-101 decreases submental fat
Sodium deoxycholate, an injectable therapy under study known as ATX-101 (Kythera) and not yet approved by the Food and Drug Administration, will present a noninvasive treatment option for patients who are concerned about the appearance of their submental fat or “double chin.”
Investigators examine benefit of level 3 dissection in melanoma
Results of a retrospective chart review revealed patients with melanoma who present with bulky axillary disease develop distant metastases very quickly, prompting the plan for a prospective study to examine the preoperative impact of shrinking tumors through the use of systemic therapy.
Parkinson’s disease treatment can cause rare adverse event
Dermatological side effects can occur with treatments for non-dermatological conditions, and consultation with a dermatologist may be a wise step in such cases.
Treating wild-type BRAF mutated melanoma poses challenges
Various approaches are being initiated to treat wild-type, BRAF mutated melanoma, according to the director of the Melanoma Program and co-leader of the Signal Transduction Program at Vanderbilt-Ingram Cancer Center in Nashville, Tenn.
PD-1, PD-L1 pathway inhibition represent melanoma treatment strategy
New research suggests that there are some potential predictive biomarkers relating to the efficacy and toxicity of emerging treatments for metastatic melanoma.
Targeted therapy, immunotherapy tackle metastatic melanoma
Targeted therapy, immunotherapy tackle metastatic melanoma
There has been a rapid revolution in the treatment of metastatic melanoma since the identification of driver oncogenes such as BRAF and its mutations more than a decade ago, according to a clinical researcher at the Vanderbilt-Ingram Cancer Center, Nashville, Tenn.
Lentigo maligna removed with wider surgical margins
Subungual melanoma can be managed without the amputation of the distal digit, according to an expert who spoke at the 7th annual Canadian Melanoma Conference.
Standardized, individualized care for melanoma does not have to be at odds
An individualized approach to medicine and standardized care in medicine do not necessarily have to be at odds when it comes to surgical management of melanoma.
Therapeutic field has been revolutionized by genetics of melanoma
Numerous therapies are making a significant difference in the management of metastatic melanoma, according to an expert who spoke at the annual Canadian Melanoma Conference.
Patient satisfaction impacts therapeutic outcome, evidence shows
A patient’s experience has been shown to impact treatment adherence and outcome, says Charles Ellis, M.D., William B. Taylor professor and associate chairman, department of dermatology, University of Michigan Health System, Ann Arbor. Therefore, it’s in the patient’s best interest for dermatologists to measure patient satisfaction.

Poll

View Results